Bladder Carcinoma Clinical Trial
Official title:
TraceIT TM Hydrogel Tissue Marker for Patients Receiving Definitive Chemoradiation for Bladder Cancer
This pilot clinical trial studies how well TracelT hydrogel works in localizing bladder tumors in patients undergoing radiation therapy for bladder cancer. TracelT hydrogel marks the location of a bladder tumor and makes it more visible during imaging tests. Using TracelT hydrogel tissue marker may help doctors learn more about tumor location and altering radiation dosage for bladder cancer.
PRIMARY OBJECTIVES: I. To utilize the TraceIT hydrogel tissue marker in localizing bladder tumors during transurethral resection of bladder tumors (TURBT). II. To improve identification of gross tumor or tumor bed location in patients receiving chemoradiation treatment for bladder cancers. SECONDARY OBJECTIVES: I. To report adverse events surrounding the placement of the TraceIT tissue marker. II. To calculate the actual dose received by the bladder tumor bed, as delineated by the hydrogel. III. To compare the dosimetric impact to the tumor bed of daily patient alignment to the pelvic bones, versus alignment to the whole bladder, versus alignment to the hydrogel markers. IV. To calculate the amount of normal tissue radiation dose decrease achievable without losing tumor coverage, with better tumor targeting with hydrogel placement. OUTLINE: Patients undergo transurethral resection of bladder tumors and receive TracelT hydrogel via injection. Patients undergo standard of care radiation therapy within 8 weeks of TracelT hydrogel placement. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Active, not recruiting |
NCT05399004 -
Evaluating Sexual Function in Women Undergoing a Radical Cystectomy for Bladder Cancer
|
||
Recruiting |
NCT03824691 -
hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study"
|
Phase 2 | |
Recruiting |
NCT04502095 -
Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy
|
Phase 4 | |
Withdrawn |
NCT05564416 -
Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial
|
Phase 2 | |
Terminated |
NCT02169284 -
Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery
|
Phase 2 | |
Recruiting |
NCT05519878 -
Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers
|
N/A | |
Active, not recruiting |
NCT02439060 -
PUBMIC (Prophylactic Use of Biologic Mesh in Ileal Conduit)
|
N/A | |
Recruiting |
NCT04410302 -
Patient-Derived Xenografts to Reduce Cancer Health Disparities
|
||
Withdrawn |
NCT04054752 -
Vaccine Response With NT-I7
|
Phase 1 | |
Terminated |
NCT03549650 -
Prevention and Management of Intravesical BCG-related Lower Urinary Tract Symptoms
|
Phase 2 | |
Completed |
NCT00469066 -
Cone Beam CT Scanning in Lung and Bladder Cancer.
|
N/A | |
Active, not recruiting |
NCT03757949 -
Nutrition Therapy in Improving Immune System in Patients With Bladder Cancer That Can Be Removed by Surgery
|
Phase 3 | |
Completed |
NCT03064308 -
The Assessment of the Feasibility of a Home Based Exercise Programme in the Older Patient Following Major Surgery
|
N/A | |
Active, not recruiting |
NCT02432963 -
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
|
Phase 1 | |
Active, not recruiting |
NCT02408406 -
PatientCareAnywhere Internet-Based Software in Improving Communication and Education in Patients With Cancer and Their Healthcare Providers
|
N/A | |
Recruiting |
NCT06109857 -
Bladder Bank (a Prospective Banking Study)
|
||
Terminated |
NCT02145390 -
Chemoradiation for Bladder Preservation After Complete Response to Neoadjuvant Chemotherapy
|
N/A | |
Terminated |
NCT01245660 -
A Phase 0 of Neoadjuvant Lapatinib in Infiltrative Bladder Carcinoma Before Cystectomy
|
Phase 0 | |
Withdrawn |
NCT02438852 -
Continuous Infusion of Ropivacaine Hydrochloride in Reducing Pain After Surgery in Patients With Bladder Cancer
|
Phase 3 |